// App-Quantinova.ai

TPS4150 : Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).

Researchers

Presenter

  • Ghassan K. Abou-Alfa

Principal Investigators

  • Ann-Lii Cheng

  • Tim Meyer

  • Anne E. Borgman-Hagey

  • Hoo Geun Chun

  • Sandrine J. Faivre

  • Junji Furuse

  • Jennifer J. Knox

  • Takuji Okusaka

  • Jerry Ping

Medical Centers

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Exelixis, Inc, South San Francisco, CA

  • Seoul St. Marys Hospital of Korea, Catholic University, Seoul, South KoreaRoyal Free Hospital, London, United KingdomUniversity of Southern California, Keck School of Medicine, Los Angeles, CA

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Hopital Beaujon, Clichy, France

Locations

  • Canada

  • Taiwan

  • Japan

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Gastric Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Propranolol

  • Sorafenib

  • Lodine

  • Propranolol/etodolac

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • III

Study Id's

  • NCT01908426

Sponsors

  • Exelixis

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved